View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 10, 2022

PhoenixMD concludes enrolment in Phase I/Ib breast cancer therapy trial

The trial is carried out at nine cancer centres in the US and dosed 41 patients.

Phoenix Molecular Designs (PhoenixMD) has concluded subject enrolment and dosing in the Phase I/Ib monotherapy trial of its PMD-026 pill being developed to potentially treat breast cancer. 

An orally available first Ribosomal S6 Kinase (RSK) inhibitor, PMD-026 was developed to potentially attack hard to treat cancers such as triple-negative breast cancer (TNBC).

The trial was carried out at nine cancer centres in the US and dosed 41 patients

These subjects were given two daily doses of PMD-026.

To establish safety and tolerability and identify the recommended Phase II dosing regimen of PMD-026 in study subjects were the primary endpoints of the trial.

A major secondary endpoint was to evaluate if the level of RSK2 expression in tumours suggests better outcomes in patients.

With the conclusion of enrolment in the trial, the company intends to progress PMD-026 into Phase II combination trials for TNBC and hormone-positive breast cancer.

Phoenix Molecular Designs founder and CEO Dr Sandra Dunn said: “The completion of patient enrolment in our Phase Ib clinical trial brings us closer to our ultimate goal of developing a therapeutic that will bring a clinically meaningful improvement to the lives of thousands of people living with TNBC. 

“We are making hope a reality as the PhoenixMD team has developed the first uniquely-engineered kinase inhibitor for TNBC based on RSK2 as a biomarker for patient selection.”

Phase I results showed that PMD-026 demonstrated to be well-tolerated in patients with breast cancer and could hinder tumour growth for up to five months.

According to preclinical data, PMD-026 was found to possess the potential to become a platform technology for chemotherapy, hormone therapy and/or immunotherapy sensitisation for several refractory cancers. 

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU